Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE – Get Free Report) saw strong trading volume on Friday . 38,827 shares traded hands during mid-day trading, a decline of 47% from the previous session’s volume of 73,103 shares.The stock last traded at $9.96 and had previously closed at $9.78.
Gyre Therapeutics Stock Performance
The company’s 50-day moving average is $13.14 and its 200 day moving average is $12.59.
Institutional Investors Weigh In On Gyre Therapeutics
Institutional investors have recently made changes to their positions in the company. Barclays PLC increased its position in shares of Gyre Therapeutics by 281.8% during the third quarter. Barclays PLC now owns 9,288 shares of the company’s stock valued at $116,000 after acquiring an additional 6,855 shares in the last quarter. Geode Capital Management LLC boosted its stake in Gyre Therapeutics by 16.9% during the 3rd quarter. Geode Capital Management LLC now owns 303,647 shares of the company’s stock valued at $3,808,000 after purchasing an additional 43,840 shares during the last quarter. State Street Corp increased its holdings in shares of Gyre Therapeutics by 8.8% in the 3rd quarter. State Street Corp now owns 104,490 shares of the company’s stock worth $1,310,000 after purchasing an additional 8,412 shares in the last quarter. FMR LLC purchased a new position in shares of Gyre Therapeutics in the third quarter worth $47,000. Finally, Advantage Alpha Capital Partners LP bought a new position in shares of Gyre Therapeutics during the third quarter valued at $334,000. Hedge funds and other institutional investors own 23.99% of the company’s stock.
Gyre Therapeutics Company Profile
Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.
Further Reading
- Five stocks we like better than Gyre Therapeutics
- Dividend Payout Ratio Calculator
- SoundHound AI: Can Its Meteoric Rise Sustain Into 2025?
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- 3 Consumer Discretionary Stocks Ready for a Comeback in 2025
- What Investors Need to Know to Beat the Market
- Top 3 Robotics and Automation Stocks for the Next AI Boom
Receive News & Ratings for Gyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
